University of California

Other

Cellegy Pharmaceuticals Inc.

Kenneth R Feingold

Peter Michael Elias

Karen Hanley

Nathan N Bass

Carl R Thornfeldt

Walter M Holleran

Janet Funk

Carl Grunfield

A method for disrupting epithelial barrier function in a host in need of the topical administration of a physiologically active substance which comprises applying to the epithelium of the host, barrier-disrupting amount of at least one agent selected from the group consisting of an inhibitor of ceramide synthesis, inhibitor of acylceramide synthesis, inhibitor of glucosylceramide synthesis, and inhibitor of sphingomyelin synthesis, an inhibitor of fatty acid synthesis, an inhibitor of cholesterol synthesis, a degradation enzyme of ceramides, acylceramide, glucosylceramides, sphingomyelin, an inhibitor of phospholipid, glycosphingolipid, including glucosylceramide, acylceramide or sphingomyelin degradation, and both inhibitors and stimulators of metabolic enzymes of free fatty acids, ceramide, and cholesterol, as well as a topical composition useful therefor are disclosed.

Methods and compositions for disrupting the epithelial barrier function

A method for disrupting epithelial barrier function in a host in need of the topical administration of a physiologically active substance which comprises applying to the epithelium of the host, barrier-disrupting amount of at least one agent selected from the group consisting of an inhibitor of ceramide synthesis, inhibitor of acylceramide synthesis, inhibitor of glucosylceramide synthesis, and inhibitor of sphingomyelin synthesis, an inhibitor of fatty acid synthesis, an inhibitor of cholesterol synthesis, a degradation enzyme of ceramides, acylceramide, glucosylceramides, sphingomyelin, an inhibitor of phospholipid, glycosphingolipid, including glucosylceramide, acylceramide or sphingomyelin degradation, and both inhibitors and stimulators of metabolic enzymes of free fatty acids, ceramide, and cholesterol, as well as a topical composition useful therefore are disclosed.

Method and compositions for disrupting the epithelial barrier function

Disorders of the skin and mucous membranes that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor &agr;, and oxysterol activators of the LXR&agr; receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.

Treatment of skin conditions with FXR activators

Treatment of skin conditions with oxysterol activators of LXR&agr;

Acne vulgaris and acneiform skin conditions are treated by the application of compounds that is juvenile hormone III, 7-methyl-9-(3,3-dimethyloxiranyl)-3-methyl-2,6-nonadienoic acid methyl ester.

FXR, PPARA and LXRA activators to treat acne/acneiform conditions

Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor .alpha., and oxysterol activators of the LXR.alpha. receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.

Treatment of skin conditions by use of PPAR.alpha. activators

Methods and compositions are provided for the treatment or prophylaxis of systematic inflammatory response syndrome by administering an antagonist to parathyroid hormone-related protein, such as antibodies to PTHrP.

Growing community of inventors

San Rafael, CA, United States of America

Kenneth R Feingold